FIGURE 1

	Mean Fluorescence Intensity		% Gated	
mAb	**L1.2-CCR5**	**PBMC**	**L1.2-CCR5**	**PBMC**
mouse IgG1	10	4	1	1
2D7	75	29	92	36
PA8	48	9	73	3
PA9	79	5	96	3
PA10	80	8	96	5
PA11	107	8	96	10
PA12	115	8	96	8
PA14	81	14	96	22

FIGURE 2

INHIBITOR COMBINATION	CONCENTRATION RATIO	ASSAY	COMBINATION INDEX	
			90% Inhibition	50% Inhibition
PA12:2D7	10:1	Entry	0.043	0.291
	2:1	Fusion	0.017	0.019
	10:1	Fusion	0.087	0.067
	50:1	Fusion	0.158	0.046
PA12:PA14	10:1	Entry	0.437	0.535
	10:1	Fusion	0.22	0.263
PA14:2D7	1:1	Entry	2.85	1.85
	1:1	Fusion	1.34	1.74
PA12:PA11	1:1	Entry	0.707	0.641
PA12:RANTES	1000:1	Fusion	0.331	0.156
PA14:RANTES	100:1	Fusion	1.6	1.37
2D7:RANTES	100:1	Fusion	0.972	0.962
PA12:CD4-IgG2	10:1	Fusion	0.3	0.31
PA14:CD4-IgG2	1:1	Fusion	0.957	0.566
2D7:CD4-IgG2	1:1	Fusion	1.127	0.302

FIGURE 3

	Epitopes	IC_{50} values (μg/ml)			
		cell-cell fusion inhibition	viral entry inhibition	gp120-binding inhibition	calcium flux inhibition
PA8	Nt	-	-	-	-
PA9	Nt/ECL2	-	-	0.24	-
PA10	Nt/ECL2	-	-	0.13	-
PA11	Nt	25.5	-	0.33	-
PA12	Nt	10.0	-	0.24	-
PA14	Nt/ECL2	1.7	.024	1.58	6.4
2D7	ECL2	1.6	.026	1.38	45

FIGURE 4


Nt
ECL1
ECL2
ECL3
2D7
PA8
PA9
PA10
PA11
PA12
PA14
76%-100+%
51%-75%
26%-50%
0%-25%
nd

FIGURE 5A


RANTES
mAbs or
PBS
PA12
PA10
PA8
PBS
2D7
PA14
Relative Fluorescence
50
100
150
200
250
300
350
400
Time (seconds)

FIGURE 5B


% inhibition of Ca^{2+} influx
100
80
60
40
20
0
1
10
100
µg/ml mAb
2D7
PA14

FIGURE 6A



FIGURE 6B


% inhibition of entry
100
80
60
40
20
0
-20
0
0.001
0.01
0.1
1
10
100
1000
µg/ml mAb
IgG1
PA8
PA9
PA10
PA11
PA12
PA14
2D7

FIGURE 6C


1400
1200
1000
800
600
400
200
0
Fluorescence
0
100
200
300
400
Concentration (nM)
b-JRFL:sCD4
b-sCD4 alone
b-JRFL alone
b-LAI:sCD4

FIGURE 6D


% inhibition gp120/sCD4 binding
100
80
60
40
20
0
0
2
4
5
10
µg/ml mAb
PA8
PA9
PA10
PA11
PA12
PA14
2D7

FIGURE 7


% inhibition of fusion
100
80
60
40
20
0
0.01
0.1
1
10
100
µg/mL mAb
2D7
PA12
2D7+PA12

FIGURE 8


percent inhibition
100
80
60
40
20
0
DP178 0.0001 0.001 0.01 0.1 1
CD4-IgG2 0.0025 0.025 0.25 2.5 25
or mixture
concentration, µg/ml

FIGURE 9

Percent Inhibition	Combination Index CD4-IgG2:T-20 Mass Ratio 25:1 (low)	25:1 (high)	5:1	1:1
95	0.32	0.20	0.22	0.50
90	0.38	0.25	0.27	0.55
85	0.43	0.29	0.30	0.59
80	0.47	0.33	0.34	0.62
75	0.51	0.36	0.37	0.65
70	0.54	0.39	0.40	0.67
65	0.58	0.42	0.43	0.70
60	0.61	0.45	0.45	0.73
55	0.65	0.48	0.49	0.75
50	0.69	0.51	0.52	0.78

FIGURE 10

Percent Inhibition	T-20 Concentration, μg/ml Alone	T-20 Concentration, μg/ml Combination	T-20 Dose Reduction	CD4-IgG2 Concentration, μg/ml Alone	CD4-IgG2 Concentration, μg/ml Combination	CD4-IgG2 Dose Reduction
99	1.1	0.17	6.6	130	4.3	29
95	0.21	0.044	4.9	19	1.10	17
90	0.10	0.024	4.2	7.8	0.59	13
70	0.025	0.0076	3.3	1.6	0.19	8.4
50	0.011	0.0039	2.8	0.60	0.095	6.3

FIGURE 11A

Percent Inhibition	Combination Index	PRO 542 Concentration, nM Alone	PRO 542 Concentration, nM Mix	PRO 542 Dose Reduction	PA12 Concentration, nM Alone	PA12 Concentration, nM Mix	PA12 Dose Reduction	T-20 Concentration, nM Alone	T-20 Concentration, nM Mix	T-20 Dose Reduction
95	0.41	10	2.1	4.8	730	2.8	260	94	19	4.9
90	0.45	7.0	1.6	4.4	320	2.1	150	63	14	4.5
70	0.47	4.1	0.92	4.5	72	1.2	60	30	8.1	3.7
50	0.48	3.1	0.66	4.7	28	0.87	32	19	5.8	3.3

PRO 542, PA12 and T-20 were used in an approximate 1:1:10 molar concentration ratio.

FIGURE 11B

Percent Inhibition	Combination Index	PRO 542 Concentration, nM Alone	PRO 542 Concentration, nM Mix	PRO 542 Dose Reduction	PRO 140 Concentration, nM Alone	PRO 140 Concentration, nM Mix	PRO 140 Dose Reduction	T-20 Concentration, nM Alone	T-20 Concentration, nM Mix	T-20 Dose Reduction
95	0.40	8.5	1.9	4.5	19	1.0	19	140	17	8.2
90	0.39	7.1	1.5	4.7	13	0.77	17	100	13	7.7
70	0.37	5.3	0.87	6.1	7.2	0.46	16	57	7.7	7.4
50	0.35	4.6	0.63	7.3	4.9	0.34	14	40	5.6	7.1

PRO 542, PRO 140 and T-20 were used in an approximate 2:1:20 molar concentration ratio.

FIGURE 11C

Percent Inhibition	Combination Index	PRO 542 Concentration, nM Alone	PRO 542 Concentration, nM Mix	PRO 542 Dose Reduction	PRO 140 Concentration, nM Alone	PRO 140 Concentration, nM Mix	PRO 140 Dose Reduction	T-20 Concentration, nM Alone	T-20 Concentration, nM Mix	T-20 Dose Reduction
95	0.24	61	2.5	24	11.9	0.72	17	156	22	7.1
90	0.22	32	1.4	23	8.4	0.40	21	96	13	7.4
70	0.19	9.8	0.50	20	4.5	0.14	32	40	4.5	8.9
50	0.18	4.7	0.26	18	3.0	0.074	41	23	2.3	10

PRO 542, PRO 140 and T-20 were used in an approximate 4:1:30 molar concentration ratio.

FIGURE 11D

Percent Inhibition	Combination Index	PRO 140 Concentration, nM Alone	PRO 140 Concentration, nM Mix	PRO 140 Dose Reduction	T-20 Concentration, nM Alone	T-20 Concentration, nM Mix	T-20 Dose Reduction
95	0.56	12	1.8	6.7	156	55	2.8
90	0.55	8.4	1.1	7.4	96	35	2.7
70	0.55	4.5	0.51	8.8	40	16	2.5
50	0.56	3.0	0.31	9.9	23	10	2.4

PRO 140 and T-20 were used in an approximate 1:30 molar concentration ratio.

FIGURE 12

Triple Combination Synergistically Blocks HIV-1 Entry (I)



FIGURE 13